According to a new report
published by Allied Market Research, titled, " Aneurysmal Subarachnoid Hemorrhage Drugs Market
by Drug Class: Global Opportunity Analysis and Industry Forecast, 20172023,"
the global aneurysmal subarachnoid hemorrhage drugs market was valued at
$160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023,
growing at a CAGR of 3.6% from 2017 to 2023.
Click Here
To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4602
Aneurysmal subarachnoid hemorrhage is a kind
of stroke, which is caused by bleeding in the subarachnoid space of the brain.
The major reasons for aneurysmal subarachnoid hemorrhage include brain
aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such
as smoking and alcohol consumption increase the risk for aSAH, as well as rise
in geriatric population are the major factors that contribute to the growth of
the market. Moreover, increase in prevalence of hypertension, and stroke
further boost the market growth. However, the associated side effects of the
drugs are expected to impede the market growth. In addition, a need to create
awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid
hemorrhage provide lucrative opportunities for the market growth.
Opioid analgesics generated the
maximum revenue, accounting for more than two-fifths share of the global
aneurysmal subarachnoid hemorrhage drugs market in 2016. The calcium channel
blockers segment is expected to witness the highest CAGR of 4.5% during the
forecast period, owing to their ability to reduce the risk of brain damage.
Key Findings of the Aneurysmal
Subarachnoid Hemorrhage Drugs Market:
- The opioid analgesics segment is expected
to grow at a significant CAGR of 2.6% during the forecast period.
- The anticonvulsants segment contributed
nearly one-fourth share of the global aneurysmal subarachnoid hemorrhage
drugs market in 2016.
- The stool softeners segment is projected
to grow at a significant CAGR of 4.2% during the forecast period.
- Germany and France are the major
shareholders, which collectively accounted for more than one-third share
of the European aneurysmal subarachnoid hemorrhage drugs market in 2016.
- Japan is the major shareholder,
accounting for more than one-third share of the Asia-Pacific aneurysmal
subarachnoid hemorrhage drugs market in 2016.
For
Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4602
The Asia-Pacific market is
projected to grow at the highest CAGR of 5.5% during the forecast period, owing
to rise in awareness about the treatment of aneurysmal subarachnoid hemorrhage
in the healthcare industry and surge in expenditures in emerging markets (such
as India and China) to cater to the unmet medical needs.
The major companies profiled in
the report are Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson
& Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer
Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd.,
and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
No comments:
Post a Comment